Vascular Biogenics Ltd.

6 articles about Vascular Biogenics Ltd.

• Vascular Biogenics Ltd. Closes Public Offering of Ordinary Shares and Pre-Funded Warrants - Apr 14, 2021

  4/14/2021

  Vascular Biogenics Ltd., announced the closing of its underwritten public offering of 6,901,790 ordinary shares, and, to certain investors in lieu thereof, pre-funded warrants to purchase 8,050,000 ordinary shares in an underwritten public offering, at a price to the public of $1.90 per ordinary share and $1.89 per pre-funded warrant.

• VBL Therapeutics Announces Positive Outcome of the Interim Analysis in the OVAL Phase 3 Ovarian Cancer Pivotal Study

  3/26/2020

  OVAL independent Data Safety Monitoring Committee (DSMC) reviewed un-blinded data and determined that the study has met the interim pre-specified criterion, of an absolute percentage advantage of 10% or higher in CA-125 response in the VB-111 treated arm compared to control. The DSMC recommends that the study proceed without modification. Overall CA-125 response rate in the first 60 randomized evaluable patients is 53%. Assuming a balanced randomization, the response rate in the treatment arm

• Vascular Biogenics Ltd. Announces Closing Of $15 Million Underwritten Offering Of Ordinary Shares And Warrants

  11/6/2015

• Vascular Biogenics Ltd. Announces Pricing Of $15 Million Underwritten Offering Of Ordinary Shares And Warrants

  11/3/2015

• Gene Therapy Biotech Vascular Biogenics Ltd. Files For A $75 Million IPO

  6/9/2014

• Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award

  8/26/2008